APPENDIX 1


32. Cufer T, Vrdoljak E, Gaafar R, et al: Phase II, open-label, randomized study (SIGN) of single-agent gefitinib (IRESSA) or docetaxel as second-line therapy in patients with advanced (stage IIIb or IV) non-small-cell lung cancer. Anticancer Drugs 17:401-9, 2006


46. Gervais R, Ducolone A, Breton JL, et al: Phase II randomised trial comparing docetaxel given every 3 weeks with weekly schedule as second-line therapy


53. Greco FA, Bonomi P, Crawford J, et al: Phase 2 study of mapatumumab, a fully human agonistic monoclonal antibody which targets and activates the TRAIL


